Tag: medications

National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Agnostic eGFR in Medication Decision-Making

NEW YORK, June 8, 2026 /PRNewswire/ -- A coalition of leading U.S. pharmacy organizations, in collaboration with the National Kidney Foundation (NKF), is urging...

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

Pudu Robotics Unveils PuduFM 1.0 and PuduAgent: Defining the Next Era of Humanoid and Embodied AI Systems

Pudu Robotics launches PuduFM 1.0 & PuduAgent, enabling "One Brain, Multiple Embodiments" for scalable service robots across industries.

Tennessee American Water Proudly Recognizes American Water Charitable Foundation 2026 Water and Environment Grantees

Recipients include three nonprofit organizations CHATTANOOGA, Tenn., June 5, 2026 /PRNewswire/ -- The American Water Charitable Foundation, a philanthropic non-profit organization established by American Water (NYSE:...

Cosmos Health Continues U.S. Expansion with Launch of Oliv18, Targeting Cardiovascular and Antioxidant Categories

Cosmos Health launches Oliv18™, a USDA and EU certified whole olive polyphenol supplement targeting cardiovascular and antioxidant categories.

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly...

Allergy & Asthma Network Statement on Centers for Medicare & Medicaid Services Work Requirements Interim Final Rule

FAIRFAX, Va., June 4, 2026 /PRNewswire/ -- Allergy & Asthma Network CEO Lynda Mitchell issued the following statement in response to the Centers for Medicare & Medicaid Services...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsMedications

InventHelp Inventor Develops New Nasal Grooming Device (HOF-871)

AG1 LAUNCHES AG1 PRO WITH CREATINE AND MORE FOR ADVANCED MUSCLE AND GUT SUPPORT

BeatBox Brings the Tropics Nationwide with Coconut Breeze Flavor Drop